There are moments of profound convergence that remind you why gatherings like ICSB matter.
This conference uniquely brings together researchers, industry leaders, and regulators, creating space not just for discussion, but for real-time alignment on complex challenges.
One such challenge that has been increasingly surfacing is the questioned safety of Ashwagandha, particularly the use of its leaves. Several countries have begun restricting or banning their use.
➡️ During ICSB, the Secretary of the Ministry of AYUSH, India, Vaidya Rajesh Kotecha, was in attendance. And in a striking coincidence, on the very day he spoke, India announced a ban on the use of Ashwagandha leaves.
That same day, Dr. Thomas Brendler presented a comprehensive safety review by a series of researchers and industry. According to the findings shared, the evidence does not indicate safety concerns with the use of Ashwagandha leaves.
It was a powerful example of why these moments matter: when evidence, expertise, and policy intersect in the same room, there is an opportunity to move toward better, more informed decisions.
My hope is that this rigorously compiled body of evidence is carefully considered, and that decisions ultimately reflect the full weight of the science. ✊ 🌿 ✅
hashtag#ICSB2026 hashtag#Ashwagandha hashtag#safety
ICSB on Ashwagandha Safety: The Evidence in the Room ⁉️🌿✅
